Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma
Conditions
Interventions
MLN2480
Locations
16
United States
San Francisco, California, United States
Denver, Colorado, United States
Augusta, Georgia, United States
Indianapolis, Indiana, United States
New York, New York, United States
Easton, Pennsylvania, United States
Start Date
September 15, 2011
Primary Completion Date
April 11, 2017
Completion Date
October 16, 2018
Last Updated
August 10, 2020
NCT07489378
NCT07181681
NCT06257264
NCT07204340
NCT07360314
NCT05969860
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions